Trial
NCT02756130
Birinapant and Carboplatin in Treating Patients and Targeting Recurrent High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (HGSOC)
Phase IWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Jonsson Comprehensive Cancer Center
Collaborators
California Institute for Regenerative Medicine (CIRM); TetraLogic Pharmaceuticals; Alpha Stem Cell Clinic (ASCC)
Condition
High Grade Fallopian Tube Serous Adenocarcinoma
Intervention
Birinapant
Why stopped
funding was not secured
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-05-13